Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2019-01-25 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
国浩律师（深圳）事务所关于公司2019年股票期权激励计划授予事项的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2019 stock option incentive plan grant of a company. It discusses the approval, authorization, grant date, grant objects, grant quantity, exercise price, and conditions of the stock option plan. The document is a legal opinion related to a capital/financing activity (stock option incentive plan) rather than a financial report, management change, or regulatory filing. It is not an announcement of a report but a substantive legal opinion on a financing-related matter. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 5706 characters, which is substantive and not a brief announcement or certification.
2019-01-25 Chinese
第三届董事会第三十次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the 30th meeting of the 3rd Board of Directors of the company. It details the meeting date, attendance, and the approval of a stock option incentive plan. It does not contain financial statements or detailed management discussion but focuses on board decisions and approvals. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors. The document is short and formal, consistent with a board meeting resolution announcement rather than a full report or regulatory filing.
2019-01-25 Chinese
关于公司2019年股票期权激励计划授予事项的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the company's 2019 stock option incentive plan grant. It includes information about the board and supervisory approvals, the conditions for granting stock options, the allocation details, performance targets, financial impact estimates, and legal and financial advisor opinions. The document is an official announcement of a capital-related event (stock option grant) rather than a full financial report or audit. It does not contain quarterly or annual financial statements or earnings highlights. The content fits best under Capital/Financing Update (CAP) as it relates to the issuance of stock options and related capital structure changes.
2019-01-25 Chinese
关于选举非独立董事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election of a non-independent director at a company's board meeting and subsequent shareholder meeting. It includes details about the nominee's background and confirms the approval of the election. There is no financial data, no mention of financial results, no audit information, and no regulatory certifications. The content focuses solely on board/management changes, specifically the nomination and election of a board member. Therefore, the document fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2019-01-23 Chinese
关于2016年限制性股票激励计划预留授予第一个解除限售期解除限售条件成就的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the achievement of the first unlocking condition of a 2016 restricted stock incentive plan by a company. It includes specifics about the stock incentive plan, the number of shares involved, the performance and legal conditions met, and approvals by the board, supervisory committee, independent directors, legal counsel, and financial advisors. The document is not a full annual or interim financial report, nor is it a simple announcement of a report. It is not a transcript, earnings release, or capital update. It is a regulatory announcement about the status and conditions of a stock incentive plan, specifically about the unlocking of restricted shares. This fits best under the category of Regulatory Filings (RNS), as it is a regulatory announcement that does not fit into other more specific categories like remuneration information or director dealings, but relates to stock incentive plan conditions and their fulfillment.
2019-01-23 Chinese
上海荣正投资咨询股份有限公司关于公司2016年限制性股票激励计划预留授予部分第一个解除限售期解除限售条件成就之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is an Independent Financial Advisor Report related to the 2016 Restricted Stock Incentive Plan of the company 健帆生物科技集团股份有限公司. It details the approval procedures, conditions for lifting stock restrictions, performance targets, and the fulfillment of these conditions. The report includes legal and regulatory references, performance assessments, and the advisor's verification opinions. It is a standalone advisory report focusing on stock incentive plan conditions and compliance, not a full annual or interim financial report, nor a simple announcement. This fits the definition of an Audit Report / Information (AR) as it involves verification and compliance opinions related to a specific financial incentive plan rather than a full financial statement or earnings release. FY 2017
2019-01-23 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.